Floatz logo

TAURURSODIOL

Wolfram Syndrome

Amylyx Pharmaceuticals Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Wolfram Syndrome cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Birmingham
Phase 2B
Depakine
Centre d'Etude des Cellules Souches
Phase 2CCC
Tirzepatide
Ospedale San Raffaele
Phase 2CCC
Dantrolene
Washington University School of Medicine
Phase 1/2CCC
Exenatide
Hadassah Medical Organization
N/AD

Same molecule, other indications

TAURURSODIOL is also rated in:

amyotrophic lateral sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →
wild type ATTR amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →